Atovaquone-Proguanil is a combination medication used to prevent and treat malaria, a parasitic disease transmitted through the bite of infected mosquitoes. The medicine combines two active substances: Atovaquone, which interferes with the energy production of malaria parasites, and Proguanil, which inhibits their ability to reproduce. Together, they provide a potent dual mechanism that targets the parasite at multiple stages of its lifecycle.<\/p>\n
This medication is effective against Plasmodium falciparum, the most dangerous and drug-resistant form of malaria. It is commonly prescribed for travellers visiting regions where malaria is endemic, as well as for short-term treatment in those who become infected.<\/p>\n
Atovaquone-Proguanil is usually taken once a day with food or a milky drink to improve absorption. For prevention, it is started one or two days before entering a malaria-risk area and continued for one week after leaving. For treatment, it is taken for three consecutive days.<\/p>\n
Compared to older malaria medications, this combination is generally well tolerated and does not require long pre-travel dosing schedules. Side effects are usually mild and may include abdominal pain, nausea, vomiting, headache, or sleep disturbances. It is not suitable for long-term prevention over several months but is ideal for shorter trips and uncomplicated treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"